Anixa Biosciences Adds UPenn's Dr. Carmen Guerra to Cancer Advisory Board — Anixa Biosciences, Inc.

Event summary

Anixa Biosciences appointed Dr. Carmen Guerra, a UPenn professor and cancer screening expert, to its Cancer Business Advisory Board on September 16, 2026.
Dr. Guerra's expertise includes increasing participation in cancer screening and clinical trials, particularly in underserved populations.
Anixa is advancing a breast cancer vaccine to Phase 2 trials and an ovarian cancer CAR-T therapy through Phase 1 trials.
The advisory board includes former American Cancer Society CEOs and the inventor of Herceptin.

The big picture

Anixa Biosciences is strengthening its advisory board with experts in cancer screening and clinical trials, aligning with its focus on advancing immunotherapies and vaccines. The addition of Dr. Guerra, known for her work in equitable cancer care, underscores the company's commitment to addressing unmet needs in breast and ovarian cancer treatment. This strategic move comes as Anixa progresses its pipeline through critical clinical phases, positioning it within the competitive landscape of oncology innovation.

What we're watching

Clinical Progress: How Dr. Guerra's guidance will accelerate Anixa's breast cancer vaccine and ovarian cancer CAR-T therapy trials.
Regulatory Pathways: Whether Anixa can leverage Dr. Guerra's FDA experience to streamline approval processes.
Strategic Partnerships: The pace at which Anixa expands collaborations with leading cancer research institutions.